These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 21848927

  • 1. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
    Skoglund C, Chéramy M, Casas R, Ludvigsson J, Hampe CS.
    Pediatr Diabetes; 2012 May; 13(3):244-50. PubMed ID: 21848927
    [Abstract] [Full Text] [Related]

  • 2. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.
    Chéramy M, Hampe CS, Ludvigsson J, Casas R.
    Clin Exp Immunol; 2013 Mar; 171(3):247-54. PubMed ID: 23379430
    [Abstract] [Full Text] [Related]

  • 3. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
    Chéramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R.
    Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
    Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J, DiAPREV-IT Study Group.
    Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
    [Abstract] [Full Text] [Related]

  • 5. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
    Ludvigsson J, Chéramy M, Axelsson S, Pihl M, Akerman L, Casas R, Clinical GAD-Study Group in Sweden.
    Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
    [Abstract] [Full Text] [Related]

  • 6. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
    Krause S, Landherr U, Agardh CD, Hausmann S, Link K, Hansen JM, Lynch KF, Powell M, Furmaniak J, Rees-Smith B, Bonifacio E, Ziegler AG, Lernmark A, Achenbach P.
    Diabetes Care; 2014 Jun; 37(6):1675-80. PubMed ID: 24598244
    [Abstract] [Full Text] [Related]

  • 7. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
    Axelsson S, Hjorth M, Akerman L, Ludvigsson J, Casas R.
    Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
    [Abstract] [Full Text] [Related]

  • 8. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
    Axelsson S, Chéramy M, Hjorth M, Pihl M, Akerman L, Martinuzzi E, Mallone R, Ludvigsson J, Casas R.
    PLoS One; 2011 Oct; 6(12):e29008. PubMed ID: 22174945
    [Abstract] [Full Text] [Related]

  • 9. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes.
    Mayr A, Schlosser M, Grober N, Kenk H, Ziegler AG, Bonifacio E, Achenbach P.
    Diabetes; 2007 Jun; 56(6):1527-33. PubMed ID: 17325256
    [Abstract] [Full Text] [Related]

  • 10. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
    Hjorth M, Axelsson S, Rydén A, Faresjö M, Ludvigsson J, Casas R.
    Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
    [Abstract] [Full Text] [Related]

  • 11. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R.
    N Engl J Med; 2008 Oct 30; 359(18):1909-20. PubMed ID: 18843118
    [Abstract] [Full Text] [Related]

  • 12. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
    Axelsson S, Chéramy M, Akerman L, Pihl M, Ludvigsson J, Casas R.
    Diabetes Care; 2013 Nov 30; 36(11):3418-24. PubMed ID: 23863909
    [Abstract] [Full Text] [Related]

  • 13. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
    Ludvigsson J, Hjorth M, Chéramy M, Axelsson S, Pihl M, Forsander G, Nilsson NÖ, Samuelsson BO, Wood T, Aman J, Ortqvist E, Casas R.
    Diabetologia; 2011 Mar 30; 54(3):634-40. PubMed ID: 21116604
    [Abstract] [Full Text] [Related]

  • 14. DPD epitope-specific glutamic acid decarboxylase (GAD)65 autoantibodies in children with Type 1 diabetes.
    Bansal N, Hampe CS, Rodriguez L, O'Brian Smith E, Kushner J, Balasubramanyam A, Redondo MJ.
    Diabet Med; 2017 May 30; 34(5):641-646. PubMed ID: 26802570
    [Abstract] [Full Text] [Related]

  • 15. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response.
    Tavira B, Cheramy M, Axelsson S, Åkerman L, Ludvigsson J, Casas R.
    Diabetologia; 2017 Jul 30; 60(7):1276-1283. PubMed ID: 28357504
    [Abstract] [Full Text] [Related]

  • 16. Autoantibodies to N-terminally Truncated GAD65(96-585): HLA Associations and Predictive Value for Type 1 Diabetes.
    Pöllänen PM, Härkönen T, Ilonen J, Toppari J, Veijola R, Siljander H, Knip M.
    J Clin Endocrinol Metab; 2022 Feb 17; 107(3):e935-e946. PubMed ID: 34747488
    [Abstract] [Full Text] [Related]

  • 17. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
    Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group.
    Lancet; 2011 Jul 23; 378(9788):319-27. PubMed ID: 21714999
    [Abstract] [Full Text] [Related]

  • 18. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
    Puente-Marin S, Dietrich F, Achenbach P, Barcenilla H, Ludvigsson J, Casas R.
    Front Immunol; 2023 Jul 23; 14():1112570. PubMed ID: 36817467
    [Abstract] [Full Text] [Related]

  • 19. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.
    Tremble J, Morgenthaler NG, Vlug A, Powers AC, Christie MR, Scherbaum WA, Banga JP.
    J Clin Endocrinol Metab; 1997 Aug 23; 82(8):2664-70. PubMed ID: 9253351
    [Abstract] [Full Text] [Related]

  • 20. Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies.
    Salami F, Spiliopoulos L, Maziarz M, Lundgren M, Brundin C, Bennet R, Hillman M, Törn C, Elding Larsson H.
    J Immunol Res; 2022 Aug 23; 2022():3532685. PubMed ID: 35664355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.